Results 11 to 20 of about 86,566 (299)

Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada. [PDF]

Journal of the International AIDS Society, 2020
IntroductionWeight gain following antiretroviral therapy (ART) initiation is common, potentially predisposing some persons with HIV (PWH) to cardio-metabolic disease.
Altoff, Keri N, Bourgi, Kassem, Crane, Heidi, Gange, Stephen J, Gill, John, Horberg, Michael A, Jenkins, Cathy A, Kirk, Gregory, Koethe, John R, Lake, Jordan, Li, Jun, Lima, Viviane D, Margolick, Joseph, Mathews, William C, Moore, Richard D, North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), Palella, Frank, Rabkin, Charles S, Rebeiro, Peter F, Silverberg, Michael, Sterling, Timothy R, Thorne, Jennifer, Willig, Amanda, Wong, Cherise   +23 more
core   +2 more sources

Clinical use of HIV integrase inhibitors : a systematic review and meta-analysis [PDF]

PLoS ONE, 2013
Background: Optimal regimen choice of antiretroviral therapy is essential to achieve long-term clinical success. Integrase inhibitors have swiftly been adopted as part of current antiretroviral regimens.
A Talbot, AJ Viera, Annemarie M. J. Wensing, AR Zolopa, Axel Fun, B Grinsztejn, B Taiwo, B Young, C Cohen, C Garrido, D McMahon, D Moher, DK Owens, DV Cordery, E DeJesus, E Martinez, E Vispo, EM Gardner, F Caby, F Canducci, F Smith, H Byakwaga, H Hatano, J Reynes, J van Lunzen, JJ Eron, JJ Eron Jr, JK Rockstroh, JL Lennox, JL Lennox, JM Gatell, JM Molina, JR Santos, L Van Wesenbeeck, L Wittkop, Linos Vandekerckhove, Luis Menéndez-Arias, M Harris, M Markowitz, M Markowitz, MA Thompson, MJ Buzon, MJ Kozal, Monique Nijhuis, N Mantel, Nele Brusselaers, O Goethals, PE Sax, Peter Messiaen, R Qaqish, R Relevo, RT Gandhi, RT Gandhi, RT Steigbigel, RT Steigbigel, S Gallien, S Nozza, V Dahl, W Towner, Y Yazdanpanah   +59 more
core   +9 more sources

HIV Integrase Inhibitors

Advances in Pharmacology, 2013
This chapter presents the discovery, development and evolution of integrase strand transfer inhibitors. A brief overview of the first‐generation inhibitors raltegravir and elvitegravir serves to describe their landmark advancement of the field and also outline areas for further improvement.
Mathieu Métifiot, Christophe Marchand, Yves Pommier   +2 more
semanticscholar   +4 more sources

Probing chelation motifs in HIV integrase inhibitors [PDF]

Proceedings of the National Academy of Sciences, 2012
A series of HIV integrase (HIV-1 IN) inhibitors were synthesized to evaluate the role of the metal-binding group (MBG) in this class of metalloenzyme inhibitors. A total of 21 different raltegravir-chelator derivative (RCD) compounds were prepared that differed only in the nature of the MBG.
Arpita, Agrawal, Jamie, DeSoto, Jessica L, Fullagar, Kasthuraiah, Maddali, Shahrzad, Rostami, Douglas D, Richman, Yves, Pommier, Seth M, Cohen   +7 more
openaire   +3 more sources

Update on Adverse Effects of HIV Integrase Inhibitors. [PDF]

Curr Treat Options Infect Dis, 2019
The goal of this paper is to provide an up-to-date review of adverse events related to the class of integrase strand transfer inhibitors (INSTIs), which became the class of choice in few years.
Kolakowska A, Maresca AF, Collins IJ, Cailhol J.   +3 more
europepmc   +2 more sources

Pharmacokinetics of HIV-Integrase Inhibitors During Pregnancy: Mechanisms, Clinical Implications and Knowledge Gaps. [PDF]

Clin Pharmacokinet, 2019
Prevention of mother-to-child transmission of HIV and optimal maternal treatment are the most important goals of antiretroviral therapy in pregnant women with HIV.
van der Galiën R, Ter Heine R, Greupink R, Schalkwijk SJ, van Herwaarden AE, Colbers A, Burger DM.   +6 more
europepmc   +2 more sources

Resistance to HIV Integrase Inhibitors: About R263K and E157Q Mutations. [PDF]

Viruses, 2018
The use of integrase inhibitors (INI) is increasing in antiretroviral therapies (ART) and INI are not all equal regarding genetic barrier to resistance.
Charpentier C, Descamps D.
europepmc   +2 more sources

HIV-2 integrase variation in integrase inhibitor-naïve adults in Senegal, West Africa. [PDF]

PLoS ONE, 2011
Antiretroviral therapy for HIV-2 infection is hampered by intrinsic resistance to many of the drugs used to treat HIV-1. Limited studies suggest that the integrase inhibitors (INIs) raltegravir and elvitegravir have potent activity against HIV-2 in ...
Geoffrey S Gottlieb, Robert A Smith, Ndeye Mery Dia Badiane, Selly Ba, Stephen E Hawes, Macoumba Toure, Alison K Starling, Fatou Traore, Fatima Sall, Stephen L Cherne, Joshua Stern, Kim G Wong, Paul Lu, Moon Kim, Dana N Raugi, Airin Lam, James I Mullins, Nancy B Kiviat, Papa Salif Sow for the UW-Dakar HIV-2 Study Group   +18 more
doaj   +1 more source

A clinical review of HIV integrase strand transfer inhibitors (INSTIs) for the prevention and treatment of HIV-1 infection

Retrovirology, 2022
Integrase strand transfer inhibitors (INSTIs) have improved the treatment of human immunodeficiency virus (HIV). There are currently four approved for use in treatment-naïve individuals living with HIV; these include first generation raltegravir ...
Alexa Vyain Zhao, R. Crutchley, R. Guduru, Kathy Ton, Tammie Lam, Amy Min   +5 more
semanticscholar   +1 more source

Prevalence of potential drug-drug interactions in patients of the Swiss HIV Cohort Study in the era of HIV integrase inhibitors.

Clinical Infectious Diseases, 2020
BACKGROUND Prevalence of potential drug-drug interactions (PDDIs) between antiretroviral drugs (ARVs) and comedications was high in 2008 in a Swiss HIV Cohort Study (SHCS) survey.
Elisabeth Deutschmann, H. Bucher, Steffen Jaeckel, S. Gibbons, K. McAllister, A. Scherrer, D. Braun, M. Cavassini, A. Hachfeld, A. Calmy, M. Battegay, M. Cipriani, L. Elzi, James B. Young, B. López-Centeno, J. Berenguer, S. Khoo, G. Moffa, C. Marzolini   +18 more
semanticscholar   +1 more source